quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:15:44·160d
SECFiling
Alaunos Therapeutics Inc. logo

SEC Form 10-Q filed by Alaunos Therapeutics Inc.

TCRT· Alaunos Therapeutics Inc.
Health Care
Original source

Companies

  • TCRT
    Alaunos Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Oct 4UpdateWells Fargo$3.00

Related

  • SEC8d
    Alaunos Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • SEC23d
    SEC Form 10-K filed by Alaunos Therapeutics Inc.
  • PR53d
    Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
  • SEC53d
    Alaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • INSIDER98d
    Director Vieser Jaime was granted 5,839 shares, increasing direct ownership by 22% to 32,338 units (SEC Form 4)
  • INSIDER98d
    Director Postma Robert W was granted 5,622 shares, increasing direct ownership by 15% to 43,872 units (SEC Form 4)
  • INSIDER98d
    Director Jerman Michael Allen was granted 5,406 shares, increasing direct ownership by 129% to 9,589 units (SEC Form 4)
  • SEC106d
    Alaunos Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022